Sudarshan Pharma Industries reported a strong second quarter for FY27, with net profit rising 77% year-on-year to Rs 7.80 crore. Revenue grew by 22.8% to Rs 205.02 crore. The company successfully migrated to the Main Board, initiated a cost-rationalization plan by closing its Palghar unit, and expanded its US footprint through a new subsidiary.
Sudarshan Pharma Q2 Profit Jumps 77% YoY to Rs 7.80 Crore
Revenue grew by 22.8% YoY to Rs 205.02 crore compared to Rs 167.01 crore in the same period last year.
Reader Takeaway: Strong top and bottom-line growth alongside strategic cost rationalization via unit closure and Main Board migration.
What just happened
Sudarshan Pharma Industries released its financial results for the quarter ended September 30, 2026. The company reported a net profit of Rs 7.80 crore, a 77.2% increase from Rs 4.40 crore in the same quarter last year. Revenue from operations climbed to Rs 205.02 crore from Rs 167.01 crore. Basic Earnings Per Share (EPS) rose to Rs 0.32.
Why this matters
The performance reflects significant operational momentum, supported by a 23.1% sequential revenue growth. The management is actively streamlining its portfolio, evidenced by the closure of the underperforming Palghar manufacturing unit, which is expected to reduce fixed costs and improve overall margins. Furthermore, the company successfully migrated from the BSE SME platform to the Main Board and listed on the NSE on October 27, 2026, marking a significant milestone in its corporate trajectory.
Strategic Developments
Beyond core results, the company is aggressively scaling globally. It incorporated Sudarshan Industries Inc. in the US earlier this year. It also divested its 51% stake in Ishwari Healthcare for Rs 1.40 crore to sharpen its focus. Capital structure remains a priority, with the company raising USD 10 million in Foreign Currency Convertible Bonds (FCCBs), part of a larger Rs 1,500 crore fundraising plan.
Risks to watch
Investors should monitor the ongoing recovery of the remaining arbitration award funds from Regans International DMCC. While Rs 7.48 crore has been received, the timely realization of the remaining balance remains a factor to watch. The impact of the Palghar plant closure on production capacity will also be key in coming quarters.
What to track next
The execution of the company's US operations and the deployment of funds raised through the FCCB route will be critical indicators for future growth.